These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38759899)

  • 1. Comprehensive analysis and characterization of glycan pairing in therapeutic antibodies and Fc-containing biotherapeutics: Addressing current limitations and implications for N-glycan impact.
    Meudt M; Baumeister J; Mizaikoff B; Ebert S; Rosenau F; Blech M; Higel F
    Eur J Pharm Biopharm; 2024 Jul; 200():114325. PubMed ID: 38759899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.
    Higel F; Sandl T; Kao CY; Pechinger N; Sörgel F; Friess W; Wolschin F; Seidl A
    Eur J Pharm Biopharm; 2019 Jun; 139():123-131. PubMed ID: 30905778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
    Liu L
    J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody-dependent cellular cytotoxicity.
    Branstetter E; Duff RJ; Kuhns S; Padaki R
    FEBS Open Bio; 2021 Nov; 11(11):2943-2949. PubMed ID: 34355537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
    Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
    Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action.
    Upton R; Bell L; Guy C; Caldwell P; Estdale S; Barran PE; Firth D
    Anal Chem; 2016 Oct; 88(20):10259-10265. PubMed ID: 27620140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
    Huang W; Giddens J; Fan SQ; Toonstra C; Wang LX
    J Am Chem Soc; 2012 Jul; 134(29):12308-18. PubMed ID: 22747414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance.
    Wang W; Soriano B; Chen Q
    Anal Biochem; 2017 Dec; 538():53-63. PubMed ID: 28947169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
    Wada R; Matsui M; Kawasaki N
    MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody.
    Giddens JP; Lomino JV; DiLillo DJ; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12023-12027. PubMed ID: 30397147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.
    Jez J; Antes B; Castilho A; Kainer M; Wiederkum S; Grass J; Rüker F; Woisetschläger M; Steinkellner H
    J Biol Chem; 2012 Jul; 287(29):24313-9. PubMed ID: 22589538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.
    Mastrangeli R; Satwekar A; Bierau H
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc glycans of therapeutic antibodies as critical quality attributes.
    Reusch D; Tejada ML
    Glycobiology; 2015 Dec; 25(12):1325-34. PubMed ID: 26263923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sculpting therapeutic monoclonal antibody N-glycans using endoglycosidases.
    Trastoy B; Du JJ; García-Alija M; Li C; Klontz EH; Wang LX; Sundberg EJ; Guerin ME
    Curr Opin Struct Biol; 2022 Feb; 72():248-259. PubMed ID: 34998123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
    Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
    MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycan engineering reveals interrelated effects of terminal galactose and core fucose on antibody-dependent cell-mediated cytotoxicity.
    Zhang Q; Joubert MK; Polozova A; De Guzman R; Lakamsani K; Kinderman F; Xiang D; Shami A; Miscalichi N; Flynn GC; Kuhns S
    Biotechnol Prog; 2020 Nov; 36(6):e3045. PubMed ID: 32627435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column.
    Kiyoshi M; Caaveiro JMM; Tada M; Tamura H; Tanaka T; Terao Y; Morante K; Harazono A; Hashii N; Shibata H; Kuroda D; Nagatoishi S; Oe S; Ide T; Tsumoto K; Ishii-Watabe A
    Sci Rep; 2018 Mar; 8(1):3955. PubMed ID: 29500371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications.
    Sjögren J; Lood R; Nägeli A
    Glycobiology; 2020 Mar; 30(4):254-267. PubMed ID: 31616919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.